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ABSTRACT
INTRODUCTION: The purpose of this study was to evaluate 
the safety and feasibility of home-based chemotherapy and 
to compare chemotherapy given at home with chemother-
apy given as an outpatient treatment in relation to toxicity, 
quality of life and patient’s preference.
METHODS: Patients who had undergone radical surgery for 
colon cancer and who were eligible to receive adjuvant 
treatment with capecitabine and oxaliplatin could be in-
cluded. To ensure patient safety, the first infusion was given 
at an outpatient clinic. Patients with adverse events graded 
≤ 2 on the Common Terminology Criteria for Adverse Events 
version 3.0 were randomised to either group A continuing 
with four treatments at home followed by three in an out-
patient clinic, or to group B continuing with three treat-
ments in an outpatient clinic followed by four at home. To 
assess quality of life, the EuroQol-5 Domain was used at 
baseline and before each treatment. Preference cards were 
used at baseline and at end of treatment.
RESULTS: A total of 51 patients were included between 
2007 and 2010. Forty-two patients continued in either 
group A or B. The nurse found that the treatment was safe 
and acceptable in all cases. In 145 cycles (99.3%), patients 
answered that they felt secure; only one patient answered: 
“Do not know”. The highest-ranking preferences for pa-
tients were transportation time followed by waiting time. 
CONCLUSIONS: Our study demonstrates that home-based 
chemotherapy is feasible and safe and that it might be a 
valuable alternative to treatment at an outpatient clinic. 
FUNDING: This study was supported by a grant from Roche.
TRIAL REGISTRATION: not relevant.
The number of cancer patients is increasing steadily 
worldwide due to a growing population with a larger 
proportion of elderly people and an increased preva-
lence of established risk factors such as smoking, over-
weight and physical inactivity [1, 2]. Along with more 
treatment options, these factors have increased pres-
sure on the healthcare system, making alternative ways 
to administer treatments an interesting topic. 
Many antineoplastic treatment regimens must be 
administered at hospitals as they require qualified staff 
and equipment in order to monitor patients during 
treatment. One way of freeing up resources for complex 
treatments may be to move less complex treatments 
out of hospital and into patients’ homes or to smaller 
primary healthcare centres. Furthermore, patients will 
benefit from this as they avoid transportation and wait-
ing time at the hospital. Despite the potential benefits of 
home-based chemotherapy, such treatment has never 
been established as standard treatment in Denmark. 
The results from trials with home-based chemotherapy 
have been summarised in reviews [3, 4]. In general, re-
sults support home-based chemotherapy as far as pa-
tients’ satisfaction, quality of life (QoL) and compliance 
are concerned. However, not all patients favour home-
based chemotherapy. Therefore, we need further ex-
ploration and additional evidence to identify which 
treatments and which patient groups may benefit from 
home-based chemotherapy [4]. 
We here focus on the feasibility and safety of 
home-based adjuvant chemotherapy for patients having 
undergone colon cancer surgery. Adjuvant treatment for 
six months with 5-fluorouracil/leucovorin or capecit-
abine together with oxaliplatin was the current world-
wide standard treatment for patients with stage III and 
high-risk stage II colon cancer when the study was con-
ducted. Furthermore, we evaluated possible differences 
in toxicity, QoL and patients’ preference between home-
based and outpatient treatment.
METHODS
Design
This was a randomised crossover study that used pa-
tients as their own controls. As severity of adverse 
events, particularly neurotoxicity, might increase during 
treatment, half of the patients started treatment at 
home and half in an outpatient clinic in order to reduce 
bias. All patients received the first treatment in the out-
patient clinic to ensure that it was well tolerated. Only 
patients with ≤ grade 2 adverse events after their first 
treatment who were willing to continue and who had an 
initial computed tomography without metastatic disease 
continued in the study. Patients were randomised in a 
1:1 ratio to continue the next seven treatments in either 
group A, with four cycles at home followed by three cy-
cles in the outpatient clinic, or to treatment in group B 
with three cycles in the outpatient clinic followed by 
four cycles at home; in total eight cycles. 
The primary endpoints were safety and feasibility. 
Secondary endpoints were toxicity, QoL and patient 
preference on selected topics. The treatment regimen 
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consisted of eight cycles of oxaliplatin 130 mg/m2, every 
three weeks and oral capecitabine 1,000 mg/m2 twice a 
day during two weeks, followed by a one-week pause. 
Oxaliplatin is normally prescribed to be given over two 
hours, but can also be given as an infusion over 30 min. 
[5]. Our study used 30-min. infusions. To avoid nausea, 
the patients were pretreated with prednisolone 50 mg 
and ondansetrone 8 mg. If these drugs proved insuffi-
cient, palonosetrone or aprepitant were prescribed. 
Diarrhoea was treated with loperamide.  
Participants and procedures
The study participants had to be more than 18 years old 
and to have been operated for stage III or high-risk stage 
II colon cancer. The exclusion criteria were patients liv-
ing more than 30 km from the hospital or receiving anti-
coagulation treatment. Home-based treatment was ad-
ministered by a study nurse with extensive oncological 
nursing experience. She carried a mobile phone allowing 
her to contact the hospital for medical advice or to call 
for emergency assistance in case of severe reactions. 
She also carried all the equipment needed for the treat-
ment, administration and handling of any potentially se-
vere reactions, including oxygen, portable suction, and 
emergency medication to treat allergic reactions. The 
set up allowed for three daily treatments. Before each 
treatment, the nurse was asked to evaluate whether it 
was considered safe and acceptable to administer the 
treatment as home-based chemotherapy. Before each 
treatment, adverse events were scored according to the 
Common Terminology Criteria for Adverse Events ver-
sion 3.0. For home-based treatments, this was done by 
the same nurse every time. The nurse made telephone 
interview the day before the planned treatment. For 
treatment in the outpatient clinic, the adverse event 
scoring was done by an oncologist, but not necessarily 
by the same person each time. The same work sheets 
for scoring adverse events were used in both settings. 
After each treatment, the patient was asked if the 
treatment was given as expected and if he or she had 
felt secure. Furthermore, the patients completed the 
EuroQol-5 Domain Health-Related Quality of Life 
Questionnaire at baseline and before each treatment. 
Patients’ preferences on seven topics were examined in 
a conjoint analysis. Ten preference cards were prepared, 
each with the seven topics in varying order. Patients 
were asked to sort the preference cards from 1 (most 
preferable) to 10 (least preferable) at baseline and at 
the final cycle (Table 1). They were not asked specific 
questions, but had to rank the following seven topics: 
transportation time, waiting time, time with doctor, 
time with nurse, safety, surroundings and contact with 
relatives.  
This study was approved by the Regional Commit-
tee on Health Research Ethics in the Capital Region of 
Denmark (record no. H-A-2007-0078). The study was 
presented to the Danish Medicines Agency, but approval 
was not deemed necessary by the Agency. Furthermore, 
approval from the Danish Data Protection Agency was 
granted (record no. 2007-41-1002). All patients provided 
their written informed consent. 
Statistics 
Data on toxicity was analysed using Fisher’s exact test 
(non-parametric). We assumed that the average sum-
marised side effect in outpatients would be of grade 2. 
In order to detect a difference between treatments, the 
true difference between treatments should be 1.25. The 
sample size was calculated using the Chow & Wang for-
mula [6]. The parameters provided to the formula were: 
significance level (adjusted for sidedness) = 0.025, stand-
TABLE 2
Patient characteristics.
Treatment A  
(N = 21)
Treatment B  
(N = 21)
Age, median (range), yrs 64 (44-76) 67 (34-80)
Gender, n (%)
Male 14 (66.7) 10 (47.6)
Female   7 (33.3) 11 (52.4)
Performance status, n (%)
0 18 (85.7) 19 (90.5)
1   3 (14.3)   2 (9.5)
Disease stage, n
Stage 2   4   6
Stage 3 17 15
Distance from hospital,  
median (range), km  
11.2 (1.9-23.0) 10.2 (3.8-32.5)
Civil status, n (%)
Married 17 (81.0) 15 (71.4)
Living alone   4 (19.0)   6 (28.6)
Get to work, n (%)
Yes 10 (47.6) 9 (42.9)
No 11 (52.4) 12 (57.1)
TABLE 1
Items and examples of preference cards.
Item Options Example
Transportation time 0, 3 or 6 h 3 h
Waiting time 0, 2 or 4 h 0 h
Time with doctor 0 and 10 min. 10 min.
Time with nurse 10 min. together with other pa-
tients or 30 min. alone
10 min. together with other pa-
tients
Safety High vs low High
Surroundings Private or in presence of others In presence of others
Contact with relatives Private or in the presence of other In the presence of other
Dan Med J 65/5  May 2018 DA N I S H M E D I C A L J O U R N A L   3
ard deviation within patients’ side effects = 2.0, power 
0.8 and minimal detectable difference in mean side ef-
fects = 1.25. A total of 43 patients will enter this two-
treatment crossover study. The probability is 80% that 
the study will detect a difference at a two-sided 0.05 sig-
nificance level.
A generalised linear model was used to analyse the 
collected health scores. The variables included were 
course of treatment, period and the interaction between 
course of treatment and period. 
A linear mixed model including both fixed and ran-
dom effects adjusted for gender and age was used to 
test the patients’ preferences.  
Trial registration: not relevant.
RESULTS
In total, 51 patients initiated treatment between No-
vember 2007 and November 2010. Nine patients were 
excluded after the first treatment. Three were excluded 
because the initial computed tomography showed meta-
static disease and six due to > grade 2 adverse events 
(abdominal pain, laryngeal spasm, intestinal thrombosis, 
diarrhoea, infection and sudden death). A total of 42 pa-
tients continued in the study as planned. Age, perfor-
mance status, tumour stage, civil status and employ-
ment status were similar in the two groups (Table 2). 
Safety and feasibility 
A total of 146 cycles were planed and given as home-
based treatment. In all cases, the study nurse found it 
safe and acceptable to administer the treatment in the 
patient’s home. One grade 2 allergic reaction was report-
ed in relation to treatments administered in the patients’ 
homes. Furthermore, one patient experienced an allergic 
reaction of grade 2 after the nurse had left, and was re-
ferred to hospital. In 16 cycles (11%), inserting a periph-
eral intravenous catheter proved to be difficult, but it 
was successfully inserted in all cases. Ten (6.9 %) patients 
had to be seen in the outpatient clinic for toxicity scoring 
as telephone interviews were inconclusive. In one case, 
the planned treatment had to be omitted as the patient 
suffered from palmar-plantar erythrodysaesthesia that 
was incorrectly scored in the telephone interview. In 
regi men A, starting with home-based chemotherapy, 
four patients withdrew from the study before cross-over, 
one due to non-compliance, one due to relapse, one due 
to a grade 2 allergic reaction and one due to grade 3 
abdom inal pain. Among patients receiving regimen B and 
starting chemotherapy in the outpatient clinic, one pa-
tient withdrew due to grade 2 cardiotoxicity. No patients 
chose to voluntarily withdraw from the study. In 145 
(99.3%) of treatments given at home, patients felt se-
cure, with only one answering “Do not know”. 
Toxicity
The severest reported adverse event from each patient 
was registered. The treatment was generally well toler-
ated with only nine patients (five in home-based and 
four in out-patient treatment) reporting grade 3 adverse 
events. There was a trend of more reported grade 2 tox-
icity in home-based treatment than in outpatient treat-
ment. The most frequent adverse event was neurotoxic-
ity which was managed by reduction or discontinuation 
of oxaliplatin. Other adverse events observed in more 
than 10% were neutropenia, diarrhoea, palmar-plantar 
erythrodysaesthesia and hand-food syndrome (Table 3). 
No significant difference was observed between the  
regimens (p = 0.34).
Quality of life
In total, 286 of 304 (94%) of the questionnaires given to 
the patients were completed and returned. QoL scores 
TABLE 3
Toxicity for the 42 patients who continued treatment after cycle one. The most severe reported adverse 
event from each patient was registered, Common Terminology Criteria for Adverse Events version 3.0. 
The values are number of patients (%).
Home-based treatment 
(21 patients, 146 cycles)
Out-patient treatment 
(21 patients, 158 cycles)
toxicity  
grade 2
toxicity 
grade 3
toxicity 
grade 2
toxicity 
grade 3
Neutropenia   5 (25) 1 (5) 2 (10)
Neurotoxicity 10 (50) 1 (5) 5 (25) 2 (10)
Diarrhoea   6 (30) 1 (5) 1 (5) 1 (5)
Palmar-plantar erythrodysaesthesia   6 (30) - 2 (10) -
Hand-foot-syndrome   4 (20) - - -
Fatigue   2 (10) - 2 (10) -
Nausea   2 (10) - 2 (10) -
Vomiting   2 (10) - - -
Infection - - 1 (5) -
Obstipation   1 (5) - 1 (5) -
Allergic reaction   1 (5) - - -
Abdominal pain - 1 (5) - -
Cardiotoxicity - - 1 (5) -
Pulmonary embolism - 1 (5) - 1 (5)
TABLE 4
Patient preferences: the variance explained by the different items. The values are %.
Significant attribute
Baseline End of treatment
group A group B group A group B
Transportation time 39 39 44 63
Waiting time 14 14   3 10
Time with doctor   1   5 -   1
Time with nurse   1   1   2 -
Safety - - -   1
Surroundings: private/hospital - - - -
Relatives: private/hospital - - - -
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during home treatment and outpatient treatment did 
not show significant differences. 
Preferences
We found no significant difference between patient 
pref erences in the two groups. The highest-ranking pref-
erence of the patients was transportation time, both at 
the start of treatment and at the end of treatment 
 (Table 4).
DISCUSSION
Patients with cancer who require treatment with che-
motherapy often experience major changes in lifestyle 
and overall well-being. Going to hospital can be time-
consuming and inconvenient, why alternative ways of 
administering treatment are interesting and relevant. 
While some chemotherapy regimens are complex and 
do require visits to the hospital, others are less complex 
and may be administered outside the hospital. However, 
guidelines are lacking in most European countries [7]. 
Treatment with capecitabine and oxaliplatin is simple 
and easily administered, and our study also confirms 
that it is feasible and safe to give these treatments at 
home. Both nurses and patients felt comfortable when 
treatments were administered in the patient’s home, 
and no severe reactions or complications were ob-
served. These results are similar to those reported from 
a Spanish study which found home-based treatment to 
be a safe alternative to outpatient treatment [8]. Our 
study used telephone interviews to score treatment tox-
icity. Approximately 7% of the patients had to be seen in 
an outpatient clinic for toxicity scoring as telephone in-
terviews were inconclusive, and in one case planned 
home-based treatment was postponed due to an incor-
rect score. Other studies have also found telephone-
based toxicity scoring to be a feasible option for patients 
receiving chemotherapy [9, 10]. However, as we ob-
served some cases of erroneous toxicity scoring, we hy-
pothesise that video conferencing, based on Skype or 
FaceTime, may be a way of improving remote toxicity 
scoring in future trials. 
There was no difference in grade 3 toxicity, but a 
trend of higher grade 2 toxicity in home-based chemo-
therapy was observed. The toxicity scoring in home-
based chemotherapy was achieved through a telephone 
interview performed by a nurse, while toxicity scoring in 
the outpatient clinic was done by a doctor. We believe 
that this trend towards a higher grade 2 toxicity in 
home-based chemotherapy was due to more exact tox-
icity scoring by the nurse at home than by the doctors at 
the hospital and that it did not reflect a real difference. 
The absence of any difference in toxicity is in accordance 
with a review by Bazian Ltd [4]. Further, we found no 
significant difference in the amount of discontinued 
treatments due to toxicity between home-based and 
outpatient treatment, which is in accordance with a pre-
vious study [8]. The present study detected no differenc-
es in QoL between home-based treatment and treat-
ment in the outpatient clinic, which is in agreement with 
two previous randomised studies [8, 11]. It should be 
pointed out that our study has a very small population, 
which makes it difficult to detect any differences. Our 
patients considered transportation and waiting time 
more important, which is in accordance with a Danish 
[12], and an Australian study [13]. The patients in our 
study ranked security and time with the doctor/nurse 
low, which is in line with a study by Lüthi et al [14], but 
in contrast to a study by Kelly et al [15]. It should be  
emphasised that the patients in our study could only 
choose selected combinations and were not allowed to 
choose freely. Like other investigations of home-based 
chemotherapy, our study was not designed to detect dif-
ferences in efficacy.
As the financial resources in healthcare continue to 
be an issue, the financial aspects of home-based treat-
ment need to be evaluated. Several studies have at-
tempted to address this question; but, the results have 
been ambiguous. Some studies demonstrate a higher 
Nurse making a telephone interview with a patient. Patient treated at home.
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cost [11], while others found no significant difference 
[16]. Home-based treatment may be resource intensive, 
with a lower throughput of patients due to transporta-
tion time and lack of ability to parallelise treatment. In 
our study, the nurse was able to administer three treat-
ments per day, which is less than in the outpatient clinic. 
A more economically viable treatment option could be 
to move treatment away from the hospitals and into 
healthcare centres. This could reduce waiting and trans-
portation time for the patients as these healthcare cen-
tres are often closer to patients’ homes than the larger 
centralised hospitals [17]. Alternatively, home-based 
treatment could be limited to patients were this is war-
ranted by their physical and/or social situation. We ex-
pect that our findings will apply to many of the patients 
receiving commonly administered chemotherapy regi-
mens, although individual factors such as patient perfor-
mance status, comorbidity and the toxicities of a specific 
chemotherapy regimen should be taken into account. 
This study has demonstrated that home-based 
chemotherapy with capecitabine and oxaliplatin is feasi-
ble and safe. However, the study has some limitations.  
It is too small to tell if there could be real a difference in 
the quality of life or toxicity between outpatient and 
home-based chemotherapy. Furthermore, the study 
cannot establish any financial aspects. 
CONCLUSIONS
Our study demonstrates that home-based chemother-
apy is feasible and safe and that it might be a valuable 
alternative to treatment at an outpatient clinic. Further, 
patients reported that minimum transportation and 
waiting time were their most important preferences.
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